OBJECTIVE: To probe into the efficacy of carrelizumab combined with albumin paclitaxel and cisplatin in the first-line treatment of patients with advanced esophageal cancer and effects on peripheral blood programmed death receptor 1（PD-1） and programmed death receptor ligand 1（PD-L1）. METHODS: Eighty patients with advanced esophageal cancer admitted to the hospital from Jul. 2019 to Oct. 2020 were extracted to be divided into the observation group and the control group at the ratio of 1∶1 according to the random number table method

with 40 cases in each group. The control group was treated with albumin paclitaxel and cisplatin

while the observation group received carrelizumab combined with albumin paclitaxel and cisplatin. The efficacy and levels of tumor markers[squamous cell carcinoma-associated antigen（SCC-Ag）

carbohydrate antigen 19-9（CA19-9）

cytokeratin 19 fragment antigen 21-1（CYFRA21-1）

carcinoembryonic antigen（CEA）]

immune function indicators[T cell subsets（CD3

+

CD4

+

CD4

+

/CD8

+

）

dendritic cells（DC）

DC/mononuclear macrophages（PBMC）]

serum PD-1

PD-L1

the core quality of life scale（QLQ-C30） score before and after treatment and the incidence of adverse reactions during treatment were compared between two groups. The survival of patients in both groups was counted at 1 year of follow-up. RESULTS: The disease control rate of the observation group was 77.50%（31/40）

significantly higher than 55.00%（22/40） of the control group

with statistically significant difference（P

<

0.05）. After treatment

the serum levels of CA19-9

CEA

CYFRA21-1 and SCC-Ag in the observation group were lower than those in the control group

the levels of CD3

+

CD4

+

CD4

+

/CD8

+

DC and DC/PBMC in the observation group were higher than those in the control group

the serum levels of PD-1 and PD-L1 in the observation group were lower than those in the control group

the QLQ-C30 score of the observation group was lower than that of the control group

with statistically significant differences（P

<

0.05）. There was no statistically significant difference in the incidence of adverse reactions between two groups（P

>

0.05）. The survival rate of the observation group was 89.47%（34/38）

higher than 70.27%（26/37） of the control group

with statistically significant difference（P

<

0.05）. CONCLUSIONS: The efficacy of carrelizumab combined with albumin paclitaxel and cisplatin in the first-line treatment of patients with advanced esophageal cancer is significant

which can effectively regulate the expression of serum PD-1 and PD-L1

improve the immune function and quality of life

reduce the levels of tumor markers

with higher safety and longer survival time.